Moderna and Merck vaccine reduces melanoma recurrence risk by 42% in trial

Left-leaning outlets emphasize the hopeful aspect, with The Guardian calling it a "foundational shift" in cancer treatment and The New York Times highlighting how it "ushers in new hope" for patients. Coverage focuses on the broader implications for other cancers and the personalized nature of the approach.

• GUThe GuardianRated Left‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial showsThe Guardian · Left
• NBCNBC NewsRated Lean LeftPersonalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trialNBC News · Lean Left
• NYTThe New York TimesRated Lean LeftMelanoma Vaccine Ushers in New Hope for Cancer PatientsThe New York Times · Lean Left
• NYTThe New York TimesRated Lean LeftMelanoma Vaccine Ushers in New Hope for Cancer PatientsThe New York Times · Lean Left
• TMTimeRated Lean LeftA Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%Time · Lean Left
• NYTThe New York TimesRated Lean LeftCancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna ReportThe New York Times · Lean Left
• APAssociated PressRated Lean LeftA novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returningAssociated Press · Lean Left · link via Google News

Center outlets present the clinical results straightforwardly, with Reuters reporting the risk reduction data and MarketWatch questioning "whether the potential new treatment is needed," focusing on the "real test" of long-term cancer prevention rather than comparison to existing drugs.

• MWMarketWatchRated CenterThe real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.MarketWatch · Center
• RTRReutersRated CenterModerna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreatReuters · Center · link via Google News
• RTRReutersRated CenterMerck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%Reuters · Center · link via Google News

Right-leaning outlets lead with dramatic framing, with Daily Mail calling it "world-first" and stating it "halves deaths from deadly skin cancer" and "slashes death risk in stunning findings." The New York Post describes it as "first-of-its-kind" and emphasizes it is "significantly reducing the chances" of tumor return.

• DMDaily MailRated Lean RightWorld-first skin cancer vaccine halves deaths from deadly skin cancer: 'It's taken a long time to get here', scientists sayDaily Mail · Lean Right
• DMDaily MailRated Lean RightWorld-first cancer vaccine slashes death risk in stunning findings led by Aussie scientistDaily Mail · Lean Right
• NYPNew York PostRated RightFirst-of-its-kind cancer vaccine helps reduce chances of melanoma patients’ tumors returning: studyNew York Post · Right